Results 81 to 90 of about 53,202 (260)

Effects of GLP-1RA Treatment on Long-Term Post-PCI Prognosis in T2DM Patients: A Propensity Score Matching Study [PDF]

Binbin Fang,1,* Fen Liu,1,* Junyi Luo,2 Ning Song,2 Chang Liu,2 Wei Ji,2 Xin An,2 Qian Xie,2 Yining Yang,3 Xiaomei Li2 1State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical ...
Li X, Song N, Yang Y, Luo J, Ji W, An X, Fang B, Liu C, Xie Q, Liu F   +9 more
core  

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

, 2022
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease and type 2 diabetes in the FIDELIO-DKD trial (NCT02540993).
Bakris, George L., Lage, Andrea, Gerasimos, Scott, Charlie, Anker, Stefan D., Ruilope, Luis M., FIDELIO-DKD Investigators, Agarwal, Rajiv, Marre, Michel, Rossing, Peter, Filippatos, Pitt, Bertram, Amod, Aslam, Joseph, Amer   +13 more
core   +1 more source

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials

Journal of Diabetes
Background The cardioprotective effects of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)‐based therapies in nondiabetic individuals with overweight or obesity remain underexplored.
Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen   +6 more
doaj   +1 more source

Perioperative Nutrition and Surgical Outcomes in Patients Receiving Glucagon-like Peptide-1 Receptor Agonists: A Scoping Review

Medicina
Background and Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for obesity and type 2 diabetes mellitus. While these agents provide substantial metabolic benefits, concerns have emerged regarding their effects
Tegbir Singh Sandha, Ofir Ron, Warren M. Rozen, Ishith Seth, Roberto Cuomo   +4 more
doaj   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Real‐world long‐term data on oral semaglutide are limited. We evaluated its 24‐month effectiveness, persistence, and safety in adults with type 2 diabetes (T2D). Materials and Methods This retrospective real‐world study included 232 adults with T2D initiating oral semaglutide at an Italian diabetes clinic.
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri, Giorgia Centorame, Luigi Piacentino, Sara Coluzzi, Gloria Formoso   +6 more
wiley   +1 more source

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.
Hussain Salim, Shaheer Qureshi, Gaurav S. Gulsin, Habib R. Khan, Saad Ahmed Waqas, Gerry P. McCann, Amit Garg, Mohammed Shurrab, Kamlesh Khunti, Muhammad Rashid   +9 more
wiley   +1 more source

Understanding the risk of diabetic retinopathy from glucagon-like peptide-1 receptor agonists: a Mendelian randomization study and systematic review of European populations

Diabetology & Metabolic Syndrome
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) are extensively prescribed to treat obesity and diabetes. However, previous studies have debated whether GLP-1RA use induces diabetic retinopathy (DR) in diabetic populations, and the ...
Baixuan Shen, Wanying Wang, Yuanhui Guo, Zilong Chen, Chuanxin Liu, Jiarui Huang, Ying Li   +6 more
doaj   +1 more source

Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Obesity is a complication of childhood craniopharyngioma that remains difficult to treat. We investigated whether semaglutide was associated with a decrease in BMI among adolescents with craniopharyngioma‐related obesity. Material and Methods This multicentre retrospective study included 20 patients < 18 years old with craniopharyngioma ...
Joanne Dornberger, Pascal Barat, Karine Aouchiche, Kevin Perge, Carine Villanueva, Sarah Castets, Natacha Bouhours‐Nouet, Aurelie Donzeau, Lucie Levaillant, Cecile Teinturier, Rachel Reynaud, Ahlam Azar‐Kolakez, Laetitia Martinerie, Dulanjalee Kariyawasam, Regis Coutant   +14 more
wiley   +1 more source